Patents by Inventor Victor Laurent

Victor Laurent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer
    Publication number: 20200081009
    Abstract: The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumour in a subject suffering from prostate cancer, comprising a step of determining the concentration or level of expression of the receptor CCR3 in a sample of prostate tumour cells obtained from said subject.
    Type: Application
    Filed: July 15, 2019
    Publication date: March 12, 2020
    Applicants: Universite Paul Sabatier (Toulouse III), Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Toulouse, Institute National de la Sante et de la Recherche Medicale (INSRM)
    Inventors: Catherine Muller, Victor Laurent, Adrien Guerard, Philippe Valet, Bernard Malavaud
  • Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer
    Patent number: 10401365
    Abstract: The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumor in a subject suffering from prostate cancer, comprising a step of determining the concentration or level of expression of the receptor CCR3 in a sample of prostate tumor cells obtained from said subject.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: September 3, 2019
    Assignees: Universite Paul Sabatier (Toulouse III), Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Toulouse, Institut National de la Sante et de la Recherche Medicale
    Inventors: Catherine Muller, Victor Laurent, Adrien Guerard, Philippe Valet, Bernard Malavaud
  • Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer
    Publication number: 20170131282
    Abstract: The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumour in a subject suffering from prostate cancer, comprising a step of determining the concentration or level of expression of the receptor CCR3 in a sample of prostate tumour cells obtained from said subject.
    Type: Application
    Filed: June 16, 2015
    Publication date: May 11, 2017
    Inventors: Catherine Muller, Victor Laurent, Adrien Guerard, Philippe Valet, Bernard Malavaud